Small and medium-sized companies (SMEs) that have done preclinical work on developing advanced therapies, such as gene or cell products, will be eligible to receive a certificate from the European Medicines Agency (EMEA) verifying that their preclinical data package meets European regulatory standards for quality and safety.
